Skip to main content

Amgen Inc(AMGN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low343.52
Day High347.68
Open:344.09
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Amgen (AMGN) Receives a Hold from Bernstein
Tipranks
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Brookdale Senior Living (BKD) and 10x Genomics (TXG)
Motley Fool
3 Catalysts That Could Send Teva Stock to $40 and Beyond
StockStory
2 S&P 500 Stocks Worth Your Attention and 1 We Ignore
LRCX
Zacks Investment Research
J&J Targets Double-Digit Growth by 2030 Despite Stelara Drag
J&J Targets Double-Digit Growth by 2030 Despite Stelara Drag
StockStory
2 Dow Jones Stocks with Exciting Potential and 1 Facing Headwinds
MCD
StockStory
2 Reasons to Like AMGN and 1 to Stay Skeptical
AMGN
Tipranks
Amgen’s FORWARD II Gout Study: What a Less Frequent Krystexxa Schedule Could Mean for Investors
Tipranks
Analysts Conflicted on These Healthcare Names: Amgen (AMGN) and Healthequity (HQY)
Tipranks
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Healthequity (HQY)
Zacks Investment Research
Should You Buy, Sell or Hold JNJ Stock Ahead of Q1 Earnings?
Should You Buy, Sell or Hold JNJ Stock Ahead of Q1 Earnings?
Tipranks
Viridian Therapeutics price target lowered to $36 from $40 at Truist
Tipranks
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Boston Scientific (BSX)
Tipranks
Analysts Offer Insights on Healthcare Companies: Pro Medicus Limited (OtherPMCUF) and Amgen (AMGN)
Motley Fool
Martin Capital Dumps $4.5 Million in Robert Half Shares After a Brutal Year for the Staffing Sector
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Amgen (AMGN), Alector (ALEC)
Tipranks
Stifel sees path towards differentiation for Viridian after Amgen data
Tipranks
Analysts’ Top Healthcare Picks: Amgen (AMGN), Airsculpt Technologies (AIRS)
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Pharvaris (PHVS)
Tipranks
Amgen Expands Thyroid Eye Disease Bet With New AMG 732 Rollover Study
Tipranks
Amgen Terminates Early-Stage AMG 378 Study: What Investors Should Watch Next
Motley Fool
2 Healthcare Dividend Stocks to Buy as the Tech-Heavy Nasdaq Dips Below Correction Territory
Motley Fool
Dow, S&P 500, Nasdaq: From Morning Meltdown to Midday "Meh"
Tipranks
Piper Sandler Reaffirms Their Buy Rating on Amgen (AMGN)
Tipranks
Wells Fargo Gives a Hold Rating to Amgen (AMGN)
Tipranks
Bernstein Reaffirms Their Hold Rating on Amgen (AMGN)
Zacks Investment Research
TEVA's Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted
TEVA's Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted
Zacks Investment Research
The Zacks Analyst Blog Roche Holding, AT&T and Amgen
The Zacks Analyst Blog Roche Holding, AT&T and Amgen
Zacks Investment Research
Top Stock Reports for Roche, AT&T & Amgen
Top Stock Reports for Roche, AT&T & Amgen
Motley Fool
This Top ETF Recently Added a Healthy Dose of These High-Yielding Dividend Stocks
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Amgen’s Rocatinlimab Trial Completion Signals Next Phase for Atopic Dermatitis Strategy

Profile

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.